Peptide P60
Based on 1 publication(s) in Google Scholar
Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4+CD25+Foxp3+ T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.39%
- CAS No.: 1319725-20-6
- Formule: C95H132N24O20S2
- Masse moléculaire:1994.34
-
Stockage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Peptide P60
More
Activité biologique
|
FOXP3 |
Peptide P60 (5 μM; 60 s association, 30 s dissociation) specifically binds to recombinant human FOXP3 protein in cell-free surface plasmon resonance assays[1].
Peptide P60 (10 μM; 2-18 min) can enter live Jurkat T cells, with its intracellular accumulation detectable within 2 min and reaching a peak at 10 min of incubation[1].
Peptide P60 (100 μM; 24 h) inhibits the nuclear translocation of transiently transfected FOXP3 in human embryonic kidney 293 cells, partially restores the NF-κB transcriptional activity suppressed by FOXP3 overexpression in human embryonic kidney 293 cells, and rescues the NFAT transcriptional activity inhibited by FOXP3 overexpression in Jurkat T cells[1].
Peptide P60 (100 μM; 3 days) inhibits the suppressive function of murine or human CD4+CD25+ regulatory T cells (Tregs), restores the proliferation of CD4+CD25− effector T cells from BALB/c mice stimulated with anti-CD3 antibody, and restores the proliferation of human peripheral blood mononuclear cells (PBMCs) stimulated with anti-CD3/CD28 magnetic beads[1].
Peptide P60 (100 μM; 3 days) inhibits the suppressive function of mouse or human CD4+CD25+ Treg cells, restores the proliferation of BALB/c mouse effector T cells in mixed lymphocyte reactions with C57BL/6 dendritic cells, and restores the proliferation of human peripheral blood mononuclear cells (PBMCs) in mixed lymphocyte reactions[1].
Peptide P60 (100 μM; 48 h) modulates gene expression in human CD4+CD25− effector T cells stimulated by anti-CD3, reduces the mRNA levels of Foxp3 and IL-10, and increases the mRNA level of IFN-γ[1].
Peptide P60 (100 μM; 48 h) upregulates IL-2 mRNA expression in human CD4+CD25+ regulatory T cells (Tregs) stimulated with IL-2 + anti-CD3, without altering the mRNA levels of Foxp3 or IFN-γ[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Jurkat T cells
-
Concentration:10 μM
-
Incubation Time:2, 4, 6, 8, 10, 14, 18 min
-
Result:Increased intracellular mean fluorescence intensity significantly over time, reaching a peak at 10 min and remaining elevated through 18 min.
Showed no significant increase in intracellular mean fluorescence intensity with the control peptide.
-
Cell Line:Human embryonic kidney 293 cells (transiently transfected with FOXP3-enhanced GFP fusion protein)
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Reduced nuclear localization of FOXP3-EGFP significantly, shifting fluorescence to the cytoplasmic compartment.
Caused no change in nuclear localization with the control peptide, and FOXP3-EGFP expression levels were equivalent across groups.
When administered in combination with the AH1 peptide vaccine, Peptide P60 (50 nM/mouse; i.p.; daily; days 0-9 post immunization) increases the tumor-free survival rate of BALB/c mice challenged with CT26 colorectal cancer cells to 82%[1].
When administered in combination with the RAdNS3 vaccine, Peptide P60 (50 nM/mouse; i.p.; daily; days 0-10 after immunization) provides complete protection against recombinant vaccinia virus HCV challenge in BALB/c mice[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR (CD1) (newborn, treated from day 1 to 10 after birth)[1]
-
Dosage:25 nM/mouse
-
Administration:i.p.; daily; day 1 to 10 after birth
-
Result:Induced scurfy-like lymphoproliferative autoimmune syndrome with massive inflammatory infiltrates in lungs, liver, and pancreas, plus splenomegaly.
Reduced spleen CD4+CD25+Foxp3+ T cell frequency to 59.3 ± 2.19% of CD4+ T cells.
Caused male mice to develop shoulder ulcers and skin hyperplasia by 3 months post-birth, with ~50% mortality by that time.
-
Animal Model:BALB/c (female, immunized with AH1 peptide, challenged with CT26 tumor cells)[1]
-
Dosage:50 nM/mouse
-
Administration:i.p.; daily; days 0-9 after immunization
-
Result:Increased splenocyte IFN-γ production in response to AH1 peptide stimulation.
Achieved 82% tumor-free survival in AH1-immunized mice challenged with CT26 tumor cells, compared to 0% in control groups.
-
Animal Model:BALB/c (female, immunized with RAdNS3, challenged with recombinant vaccinia virus vHCV1-3011)[1]
-
Dosage:50 nM/mouse
-
Administration:i.p.; daily; days 0-10 after immunization
-
Result:Provided 100% protection against vHCV1-3011 challenge, with significantly reduced ovarian viral loads compared to RAdNS3-only, saline, or control peptide groups.
Chemical Information
-
CAS No. 1319725-20-6
-
Appearance Solid
-
Masse moléculaire 1994.34
-
Formule C95H132N24O20S2
-
Color White to off-white
-
Synonyms
FOXP3 inhibitor P60
-
Sequence
Arg-Asp-Phe-Gln-Ser-Phe-Arg-Lys-Met-Trp-Pro-Phe-Phe-Ala-Met
-
Sequence Shortening
RDFQSFRKMWPFFAM
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Cell Death Discov
CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells. [Abstract]2026 Mar 28. PMID: 41896541
Solvant et solubilité
DMSO : 50 mg/mL (25.07 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.5014 mL | 2.5071 mL | 5.0142 mL | 12.5355 mL |
| 5 mM | 0.1003 mL | 0.5014 mL | 1.0028 mL | 2.5071 mL | |
| 10 mM | 0.0501 mL | 0.2507 mL | 0.5014 mL | 1.2535 mL | |
| 15 mM | 0.0334 mL | 0.1671 mL | 0.3343 mL | 0.8357 mL | |
| 20 mM | 0.0251 mL | 0.1254 mL | 0.2507 mL | 0.6268 mL | |
| 25 mM | 0.0201 mL | 0.1003 mL | 0.2006 mL | 0.5014 mL |
Powered by Bioz